These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Factorial study of the efficacy of cholestyramine, L-tryptophan and clofibrate in human nephrotic hyperlipidaemia. Schapel GJ; Edwards KD; Neale FC Prog Biochem Pharmacol; 1974; 9():82-98. PubMed ID: 4438384 [No Abstract] [Full Text] [Related]
3. [Nephrotic hyperlipidemia and its clinical significance]. Neverov NI; Srinivas KV Ter Arkh; 1990; 62(6):150-3. PubMed ID: 2218917 [No Abstract] [Full Text] [Related]
4. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. Wheeler DC J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150 [TBL] [Abstract][Full Text] [Related]
5. [Lipolytic activity of kidney tissue in experimental nephrotic syndrome]. Leĭtes SM; Nikiforova NV Vopr Med Khim; 1967; 13(4):404-8. PubMed ID: 5598540 [No Abstract] [Full Text] [Related]
6. [Therapy of hyperlipidemia]. Müller G Dtsch Gesundheitsw; 1971 Oct; 26(43):2020-4. PubMed ID: 4947270 [No Abstract] [Full Text] [Related]
7. Clofibrate and androsterone effect on serum lipids. Orgain ES; Bogdonoff MD; Cain C Arch Intern Med; 1967 Jan; 119(1):80-5. PubMed ID: 6015838 [No Abstract] [Full Text] [Related]
8. [Hyperlipemia in nephrotic syndrome]. Walasek L Pol Tyg Lek; 1972 Jan; 27(5):189-91. PubMed ID: 4551652 [No Abstract] [Full Text] [Related]
9. [The treatment of essential hyperlipidemia with clofibrate]. Reuter W; Seifert A Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:184-7. PubMed ID: 4918619 [No Abstract] [Full Text] [Related]
10. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)]. Sterner W; Chibanguza G; Metz G Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056 [TBL] [Abstract][Full Text] [Related]
11. [Dyslipidemia in the nephrotic syndrome. Physiopathological aspects and therapeutic prospects]. Campanacci L Minerva Nefrol; 1975; 22(6):243-51. PubMed ID: 1223701 [No Abstract] [Full Text] [Related]
12. [Hyperlipoproteinemia in the nephrotic syndrome]. Yasugi T; Shimizu T; Iijima M; Tomita M; Harada M Saishin Igaku; 1972 Mar; 27(3):504-9. PubMed ID: 5021394 [No Abstract] [Full Text] [Related]
13. Hypolipidaemic action of gemfibrozil in adult nephrotics. Eisalo A; Manninen V; Mälkönen M; Kuhlbäck B Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):47-8. PubMed ID: 798197 [No Abstract] [Full Text] [Related]
14. The influence of drugs affecting lipids on atherosclerosis. Ditschuneit H Horm Metab Res; 1974; Suppl 4():191-4. PubMed ID: 4421312 [No Abstract] [Full Text] [Related]
15. Pathogenesis of lipid abnormalities in patients with nephrotic syndrome/proteinuria: clinical implications. Warwick GL; Packard CJ Miner Electrolyte Metab; 1993; 19(3):115-26. PubMed ID: 8232098 [TBL] [Abstract][Full Text] [Related]